These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37871778)

  • 21. Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
    Lee J; Melch M; Robbie GJ
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):842-852. PubMed ID: 36883675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Competition potency of siRNA is specified by the 5'-half sequence of the guide strand.
    Yoo JW; Kim S; Lee DK
    Biochem Biophys Res Commun; 2008 Feb; 367(1):78-83. PubMed ID: 18164261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
    Ranasinghe P; Addison ML; Dear JW; Webb DJ
    Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Lu J; Swearingen E; Hardy M; Collins P; Wu B; Yuan E; Lu D; Li CM; Wang S; Ollmann M
    Mol Ther Nucleic Acids; 2022 Jun; 28():423-434. PubMed ID: 35505960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor-Specific Delivery of Peptide Nucleic Acids Conjugated to Three Sequentially Linked
    Bhingardeve P; Madhanagopal BR; Naick H; Jain P; Manoharan M; Ganesh K
    J Org Chem; 2020 Jul; 85(14):8812-8824. PubMed ID: 32529829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.
    Wei J; Jones J; Kang J; Card A; Krimm M; Hancock P; Pei Y; Ason B; Payson E; Dubinina N; Cancilla M; Stroh M; Burchard J; Sachs AB; Hochman JH; Flanagan WM; Kuklin NA
    Mol Pharmacol; 2011 Jun; 79(6):953-63. PubMed ID: 21427169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Components and assembly of RNA-induced silencing complex].
    Song XM; Yan F; Du LX
    Yi Chuan; 2006 Jun; 28(6):761-6. PubMed ID: 16818443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria.
    Melch M; Lee J; Jomphe C; Robbie GJ
    Clin Pharmacokinet; 2023 Jan; 62(1):89-99. PubMed ID: 36633811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells.
    Vickers TA; Lima WF; Nichols JG; Crooke ST
    Nucleic Acids Res; 2007; 35(19):6598-610. PubMed ID: 17905815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent RNAi by short RNA triggers.
    Chu CY; Rana TM
    RNA; 2008 Sep; 14(9):1714-9. PubMed ID: 18658119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.
    Janas MM; Harbison CE; Perry VK; Carito B; Sutherland JE; Vaishnaw AK; Keirstead ND; Warner G
    Toxicol Pathol; 2018 Oct; 46(7):735-745. PubMed ID: 30139307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment.
    Xu R; Njumbe Ediage E; Verhaeghe T; Snoeys J; Dillen L
    Nucleic Acid Ther; 2024 Aug; 34(4):199-210. PubMed ID: 38638105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA helicase A is not required for RISC activity.
    Liang XH; Crooke ST
    Biochim Biophys Acta; 2013 Oct; 1829(10):1092-101. PubMed ID: 23895878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competition for RISC binding predicts in vitro potency of siRNA.
    Koller E; Propp S; Murray H; Lima W; Bhat B; Prakash TP; Allerson CR; Swayze EE; Marcusson EG; Dean NM
    Nucleic Acids Res; 2006; 34(16):4467-76. PubMed ID: 16945958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
    Holm A; Løvendorf MB; Kauppinen S
    Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient construction of an inverted minimal H1 promoter driven siRNA expression cassette: facilitation of promoter and siRNA sequence exchange.
    Nassanian H; Sanchez AM; Lo A; Bradley KA; Lee B
    PLoS One; 2007 Aug; 2(8):e767. PubMed ID: 17712415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GalNAc bio-functionalization of nanoparticles assembled by electrostatic interactions improves siRNA targeting to the liver.
    Korin E; Bejerano T; Cohen S
    J Control Release; 2017 Nov; 266():310-320. PubMed ID: 28987883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.
    Foster DJ; Brown CR; Shaikh S; Trapp C; Schlegel MK; Qian K; Sehgal A; Rajeev KG; Jadhav V; Manoharan M; Kuchimanchi S; Maier MA; Milstein S
    Mol Ther; 2018 Mar; 26(3):708-717. PubMed ID: 29456020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs.
    Boianelli A; Aoki Y; Ivanov M; Dahlén A; Gennemark P
    Nucleic Acid Ther; 2022 Dec; 32(6):507-512. PubMed ID: 35867041
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.